News
US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback